Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. 2021

Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
Department of Nephrology, Dialysis and Transplantation, Hospital University of Limoges, Limoges, France.

Kidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and rates of seroconversion after vaccination are lower among patients with CKD and those taking immunosuppressants compared with controls. Data are lacking regarding their humoral response to vaccination to prevent COVID-19. This investigation of early serological response after COVID-19 vaccination with the Pfizer/BioNTech (BNT162b2) mRNA vaccine included 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and seven healthy controls. We recorded data from the medical file for various clinical parameters, including response to hepatitis B vaccination, and measured antibody titers against SARS-CoV-2 at 0, 14, 28, 36, and 58 days after the first injection. In controls, we detected antibodies at a positive level (>13 arbitrary units per ml; AU/ml) at day 14 postinjection, which increased progressively to peak at day 36 (1082 AU/ml; interquartile range [IQR], 735.0-1662.0). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/ml; IQR, 83.4-526.0). We detected a positive antibody level in only three transplant recipients at day 36. In patients on hemodialysis, those aged <75 years had a higher antibody response versus those aged >75 years, and serum albumin and Kt/V were positively correlated with serological response (P<0.04 and P<0.0, respectively); nonresponders to HBV vaccine had the lowest anti-SARS-CoV-2 antibody titers. Our results suggest that the postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, and is reduced by the uremic condition in patients undergoing hemodialysis.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19

Related Publications

Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
August 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
November 2022, Transplantation proceedings,
Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
February 2022, Pediatric nephrology (Berlin, Germany),
Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
March 2023, Pediatric nephrology (Berlin, Germany),
Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
January 2023, Transplant international : official journal of the European Society for Organ Transplantation,
Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
March 2024, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
November 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
December 2021, Clinical chemistry,
Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
November 2022, Transplantation direct,
Clément Danthu, and Sébastien Hantz, and Arthur Dahlem, and Marion Duval, and Bacary Ba, and Manon Guibbert, and Zhour El Ouafi, and Séverine Ponsard, and Insaf Berrahal, and Jean-Michel Achard, and Frédérique Bocquentin, and Vincent Allot, and Jean-Philippe Rerolle, and Sophie Alain, and Fatouma Touré
April 2022, Scientific reports,
Copied contents to your clipboard!